Avineuro Announced Advancing Potent Small Molecule For Treatment Of Alzheimer's Disease To Clinical Development

Main Category: Alzheimer's / Dementia
Also Included In: Clinical Trials / Drug Trials;  Conferences;  Pharma Industry / Biotech Industry
Article Date: 04 Nov 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009. Results of the studies will be presented at the 9th International Conference -- AD/PD 2009 -- Prague, Czech Republic, March 11-15, 2009.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.

Avineuro Pharmaceuticals, Inc.
http://www.avineuro.com